<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05082766</url>
  </required_header>
  <id_info>
    <org_study_id>DefenAge-2021-01</org_study_id>
    <nct_id>NCT05082766</nct_id>
  </id_info>
  <brief_title>Improvement in the Appearance of Periorbital Wrinkles</brief_title>
  <official_title>Improvement in the Appearance of Periorbital Wrinkles With DefenAge 8-in-1 BioSerum Supplemented With Enhanced Concentration of Defensins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goldman, Butterwick, Fitzpatrick and Groff</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Advanced Dermatology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MediCell Technologies, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Goldman, Butterwick, Fitzpatrick and Groff</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of DefenAge 8-in-1 BioSerum&#xD;
      supplemented with the enhanced concentration of defensins (enhanced 8-in-1 BioSerum) in the&#xD;
      improvement of periorbital wrinkles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled subjects will all receive enhanced DefenAge 8-in-1 BioSerum to be applied on the&#xD;
      face including periorbital area.&#xD;
&#xD;
      Subjects satisfying all inclusion and exclusion criteria will be enrolled in this trial.&#xD;
      Prior to receiving any study treatment, mandatory photography using Canfield Vectra 3D and&#xD;
      VISIA. Patients will return for follow-up assessments at Day 30, 60, and 90.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 11, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>will be treated with the enhanced DefenAge 8-in-1 BioSerum to their entire face</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician evaluator assessment of change using Fitzpatrick-Goldman Classification of Wrinkling and Degree of Elastosis Scale</measure>
    <time_frame>baseline, Day 30, Day 60, and Day 90</time_frame>
    <description>measurements will be completed based on images captured at baseline, Day 30, Day 60, and Day 90 and assessed by a blinded evaluator using the Fitzpatrick-Goldman Classification of Wrinkling and Degree of Elastosis Scale where wrinkling ranges from class 1 (fine wrinkles) to class 3 (Fine to deep wrinkles, numerous lines, with or without redundant skin folds) and Elastosis ranges from 1-3 (mild) to 7-9 (severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Asses the change of Percent of improvement at different time points</measure>
    <time_frame>Day 30, Day 60, and Day 90</time_frame>
    <description>Percent improvement in periorbital wrinkles, laxity, pigmentation, erythema, texture, and radiance conducted by an evaluator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed Global Aesthetic Improvement Score (I-GAIS)</measure>
    <time_frame>Day 30, 60 and 90</time_frame>
    <description>Investigator-assessed Global Aesthetic Improvement Score based on photographs where scale is 1 (much improved) to 5 (much worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Global Aesthetic Improvement Score (S-GAIS)</measure>
    <time_frame>Day 30, 60 and 90</time_frame>
    <description>Subject Global Aesthetic Improvement Score Day 30, 60 and 90 using photographs where scale is 1 (much improved) to 5 (much worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator assessment of tolerability of study drug including erythema, burning/stinging, dryness, peeling (desquamation), and tenderness</measure>
    <time_frame>Day 30, 60 and 90.</time_frame>
    <description>Investigator assessment of tolerability of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient questionnaire</measure>
    <time_frame>Day 30, 60 and 90.</time_frame>
    <description>Self-Assessment questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Periorbital Wrinkles</condition>
  <arm_group>
    <arm_group_label>DefenAge 8-in-1 BioSerum supplemented with enhanced concentration of defensins</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled subjects will all receive enhanced DefenAge 8-in-1 BioSerum to be applied on the face including periorbital area.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enhanced DefenAge 8-in-1 BioSerum</intervention_name>
    <description>DefenAge is a topical skincare brand containing a composition of biologically active natural molecules, named defensins, that repair skin damage associated with aging.</description>
    <arm_group_label>DefenAge 8-in-1 BioSerum supplemented with enhanced concentration of defensins</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects in general good health greater than 30 years of age&#xD;
&#xD;
          -  Must be willing and capable of giving consent and signing an Informed Consent Form&#xD;
&#xD;
          -  Subjects with moderate to severe periorbital wrinkles (at least a grade II in wrinkles&#xD;
             and score of 4 in elastosis on the Fitzpatrick-Goldman wrinkle scale)&#xD;
&#xD;
          -  Female Subjects will be either of non-childbearing potential defined as:&#xD;
&#xD;
               1. Having no uterus&#xD;
&#xD;
               2. No menses for at least 12 months&#xD;
&#xD;
               3. Bilateral tubal ligation Or; (WOCBP) women of childbearing potential, must have&#xD;
                  had a regular menstrual cycle prior to study entry. All systemic birth control&#xD;
                  measures must be in consistent use at least 6 months prior to study&#xD;
                  participation. WOCBP must agree to use an effective method of birth control&#xD;
                  during the course of the study, such as:&#xD;
&#xD;
               1. Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine&#xD;
                  device&#xD;
&#xD;
               2. Intrauterine coil&#xD;
&#xD;
               3. Barrier method used with an additional form of contraception (e.g., sponge,&#xD;
                  spermicide or condom)&#xD;
&#xD;
               4. Abstinence or same sex partner (If practicing abstinence or sexual activity with&#xD;
                  a same sex partner, must agree to use barrier method described above (c) if&#xD;
                  becomes sexually active with a non-vasectomized male partner).&#xD;
&#xD;
               5. Vasectomized male partner (for at least 6 months) (must agree to use barrier&#xD;
                  method described above (c) if becomes sexually active with un-vasectomized male&#xD;
                  partner).&#xD;
&#xD;
          -  Negative urine pregnancy test results at Baseline prior to study entry (if applicable)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of sensitivity to any ingredient in DefenAge 8-in-1 BioSerum.&#xD;
&#xD;
          -  Subjects receiving any topical cosmetic anti-wrinkle and/or skin lightening products&#xD;
             known to affect skin aging such as products containing hydroquinone, vitamin A&#xD;
             derivatives (retinol, tretinoin, adapalene, tazarotene), alpha/beta/poly-hydroxy acids&#xD;
             (salicylic acid, glycolic acid etc.), vitamins C or D (includes derivatives thereof),&#xD;
             arbutin, retinol, azelaic acid, kojic acid, licorice extracts, bearberry extracts,&#xD;
             mequinol) on the treatment area within 14 days prior to or during the study period,&#xD;
             other than the study product.&#xD;
&#xD;
          -  Subjects using any topical imiquimod, 5-fluorouracil, or diclofenac on their face&#xD;
             within 12 weeks prior to or during the study period&#xD;
&#xD;
          -  Subjects who have had a microdermabrasion (light or medium skin peel on their face&#xD;
             within 30 days prior to or during the study period&#xD;
&#xD;
          -  Subjects receiving a chemical peel, a non-ablative laser, light, radiofrequency, or&#xD;
             ultrasound treatment on their face must have discontinued the drug/treatment at least&#xD;
             3 months prior to entering the study&#xD;
&#xD;
          -  Subjects receiving Dermabrasion (deep skin peel) and/or ablative laser treatments on&#xD;
             their face, and systemic retinoids must have discontinued the drug/treatment at least&#xD;
             6 months prior to entering the study&#xD;
&#xD;
          -  History of or the presence of any skin condition/disease that might, in the opinion of&#xD;
             the investigator, interfere with the diagnosis or evaluation of study parameters&#xD;
             (i.e., acne, atopic dermatitis, eczema, psoriasis, seborrheic dermatitis)&#xD;
&#xD;
          -  Subjects with current actinic keratoses or any other skin cancer(s) in the treatment&#xD;
             areas&#xD;
&#xD;
          -  Subjects with a significant history or current evidence of a medical, psychological or&#xD;
             other disorder that, in the investigator's opinion, would preclude enrollment into the&#xD;
             study&#xD;
&#xD;
          -  Subjects with any active systemic disease that is not yet deemed medically stabilized&#xD;
&#xD;
          -  Subjects with an active bacterial, fungal, or viral infection&#xD;
&#xD;
          -  Subjects participating or completing participation in a clinical trial within 30 days&#xD;
             prior to or during the study period&#xD;
&#xD;
          -  A female subject who is currently breast-feeding, nursing, pregnant or planning to&#xD;
             becoming pregnant during the study period&#xD;
&#xD;
          -  Subjects not willing to comply with study dosing and complete the entire course of the&#xD;
             study&#xD;
&#xD;
          -  Subjects not willing to avoid extended periods of sun exposure for the duration of the&#xD;
             study (including tanning beds). During the study, when excessive sun exposure is&#xD;
             unavoidable, subjects should wear appropriate protective clothing and use the&#xD;
             dispersed sunscreen&#xD;
&#xD;
          -  Subjects who have had treatment with neuromodulators (ex. Botox, Dysport, or Xeomin)&#xD;
             anywhere on the face within 6 months prior to or during the study period.&#xD;
&#xD;
             18. Subjects who have had treatment with fillers anywhere on the face, or other forms&#xD;
             of facial soft tissue augmentation (ex. Fat transfer) within 6 months prior to or&#xD;
             during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>31 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabrina G Fabi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cosmetic Laser Dermatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherif Mikhail, MD</last_name>
    <phone>8586571004</phone>
    <email>SMikhail@CLDerm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West Dermatology Research Center/Cosmetic Laser Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Pacheco</last_name>
      <phone>858-657-1004</phone>
      <phone_ext>143</phone_ext>
      <email>apacheco@clderm.com</email>
    </contact>
    <contact_backup>
      <last_name>Sherif Mikhail, MD</last_name>
      <phone>858 657 1004</phone>
      <email>smikhail@westderm.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sabrina Fabi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Taub A, Bucay V, Keller G, Williams J, Mehregan D. Multi-Center, Double-Blind, Vehicle-Controlled Clinical Trial of an Alpha and Beta Defensin-Containing Anti-Aging Skin Care Regimen With Clinical, Histopathologic, Immunohistochemical, Photographic, and Ultrasound Evaluation. J Drugs Dermatol. 2018 Apr 1;17(4):426-441.</citation>
    <PMID>29601620</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wrinkles</keyword>
  <keyword>crow's feet</keyword>
  <keyword>face wrinkles</keyword>
  <keyword>face</keyword>
  <keyword>cosmetic</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Possibly Efficacy Data-endpoints</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

